What is the therapeutic effect of Nintedanib/Vigat and what is the feedback from patients?

Nintedanib (Nintedanib) is a multi-target tyrosine kinase inhibitor that was initially developed for anti-tumor treatment. Later, it was widely used in a variety of pulmonary fibrotic diseases due to its inhibitory effects on angiogenesis and fibrosis pathways. The drug is currently mainly used to treat idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD) and chronic fibrosing interstitial lung disease (PF-ILD) with a progressive phenotype. Globally, nintedanib has been regarded as one of the important drugs to control the progression of pulmonary fibrosis.

Based on overseas clinical and patient feedback, the main therapeutic value of nintedanib lies in delaying disease progression. For patients with idiopathic pulmonary fibrosis, long-term use can slow down the decline of lung function and reduce the risk of acute exacerbation. Although fibrotic lesions cannot yet be reversed, the drug's "stabilizing effect" allows many patients to maintain better respiratory function for longer periods of time and delay the need for oxygen therapy or transplantation.

Patients generally report that nintedanib may cause some discomfort in the early stages of taking it, especially gastrointestinal reactions, such as mild diarrhea or nausea. This is due to the effect of the drug on multi-target pathways, but most patients can gradually adapt after dose adjustment or dietary regulation. Doctors usually closely observe tolerance in the early stages of treatment to ensure the safety and effectiveness of the drug for long-term use.

In addition, some patients have reported that after several months of continuous treatment, their dyspnea symptoms have improved and their exercise tolerance has become stronger than before. This improvement resulted more from a slowdown in disease progression than from a reversal of fibrosis. Many long-term users believe that although the drug cannot "cure" pulmonary fibrosis, it can help them cope with the disease process more smoothly and improve their quality of life and psychological confidence.

Keyword tag: nintedanib Therapeutic effect Patient feedback Anti-fibrosis Pulmonary fibrosis Drug experience

Reference materials:https://en.wikipedia.org/wiki/Nintedanib